[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633912":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":24,"collaborators":10,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":42,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"invasive fungal infection patients",null,"Severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy",[13],"Other: Collection of pharmacokinetic samples to explore the pharmacokinetic characteristics in severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Collection of pharmacokinetic samples to explore the pharmacokinetic characteristics in severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"wenjuan miao, Doctor","CONTACT","+86 18622691362","miaowenjuan@ihcams.ac.cn",{"type":25,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100633912","study-on-the-pharmacokinetic-characteristics-of-liposomal-amphotericin-b-in-patients-with-invasive-fungal-infections-undergoing-plasma-exchange-therapy-100633912",false,"NCT07532850","Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy","Study on the Pharmacokinetic Characteristics, Safety, and Efficacy of Liposomal Amphotericin B in Critically Ill Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy","Inclusion Criteria:\n\nAge ≥ 18 years old, gender not limited; According to \\\u003C The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision) \\>, the diagnosis is neutropenia with fever, possible, probable, and proven IFD invasive fungal disease;\n\n* Currently receiving treatment with liposomal amphotericin B;\n* Undertaking plasma exchange support therapy;\n* Understand the research procedure and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nConfirmed patients with allergies\u002Frapid onset severe allergic reactions\u002Fintolerance to AmB Subjects who are known to be insensitive or resistant to amphotericin B treatment, such as those with invasive Aspergillus terreus and Aspergillus nidulans\n\n\\-","ALL","18 Years",{"count":36,"type":37},10,"ESTIMATED","OBSERVATIONAL","The goal of this prospective study is to describe the pharmacokinetic characteristics of liposomal amphotericin B during plasma exchange therapy for severe invasive fungal infections in Chinese patients, preliminarily explore the influencing factors of in vivo exposure variability of liposomal amphotericin B, and integrate the findings with efficacy and safety outcomes.\n\nThe main questions it aims to answer is: Clarifying the correlation between the concentration, efficacy, and safety of different forms of liposomal amphotericin B in a special population, explore the changes in drug concentration mediated by plasma exchange, elucidate the mechanism of individual differences in efficacy and the optimal dosage, in order to provide a basis for personalized treatment of liposomal amphotericin B.\n\nThe study plans to collect pharmacokinetic samples from 10 adult (aged ≥ 18 years) severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.",[41],"Invasive Fungal Infections",[43,44,45,46],"plasma exchange","invasive fungal infection","liposomal amphotericin B","pharmacokinetics","NOT_YET_RECRUITING","2026-04-13",{"date":50,"type":51},"2026-04-16","ACTUAL",{"date":53,"type":37},"2026-03-30",{"date":55,"type":37},"2027-06-30",{"name":5,"class":6}]